Page 1

PRESS RELEASE innate pharma INNATE PHARMA THIRD QUARTER 2021 REPORT Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca's randomized Phase 2 COAST study in unresectable , Stage III NSCLC , advancing to Phase 3 Pre - clinical data presented at SITC with Sanofi from the lead next generation NK cell engager platform , ANKETTM targeting CD123 in acute myeloid leukemia Cash position of € 141.8 million¹ as of September 30 , 2021 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Marseille , France , November 16 , 2021 , 7:00 AM CET Innate Pharma SA ( Euronext Paris : IPH ; Nasdaq : IPHA ) ( “ Innate " or the " Company " ) today announced its revenues and cash position for the first nine months of 2021 . " In the period , we continued to execute against our strategic priorities as we reported readouts from two of our partnered portfolio programs . This included randomized Phase 2 data for monalizumab in combination with durvalumab in unresectable , Stage III NSCLC as well as pre - clinical data from our lead ANKET molecule targeting CD123 in acute myeloid leukemia . These readouts continue to set the stage for delivering both near and long - term value , while also highlighting the strength and depth of our core R & D efforts , " said Mondher Mahjoubi , Chief Executive Officer of Innate Pharma . " Looking ahead , we will continue to advance our lacutamab development program and move our early stage R & D activities towards the clinic with our next generation ANKET platform . We also look forward to seeing AstraZeneca's upcoming plans for monalizumab's registrational study in unresectable , Stage III NSCLC , which further reinforces our strategy of building a sustainable business with a robust R & D engine . " Webcast and conference call will be held today at 2:00 p.m. CET ( 8:00 a.m. ET ) The live webcast will be available at the following link : https://event.on24.com/wcc/r/3492971/A9D12AE41D08D16F4096ACD3C27EC089 Participants may also join via telephone using the following dial in numbers : France dial - in number : +33 8056 20 704 United States : +1 646 904 5544 All other locations : +1 929 526 1599 Access code : 043615 This information can also be found on the Investors section of the Innate Pharma website , www.innate pharma.com . A replay of the webcast will be available on the Company website following the event . 1 Including short term investments ( € 15.8 million ) and non - current financial instruments ( € 39.9 million ) Page 1/6